Quest Diagnostics Incorporated Stock News

SECAUCUS, N.J. , Sept. 8, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Sam Samad, Executive Vice Pre

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Covid-19 related stocks started spiking again this week. Driven primarily by reports about new variants and increasing spread.

Quest Diagnostics has a strong Q2 with a slight beat on EPS and revenue. Quest's base business appears to be recovering from the pandemic and pulled in $2.30B in revenue. Despite fading COVID-related

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.

Biogen and Eli Lilly both have treatments to help reduce cognitive decline in Alzheimer's patients. But the key to their effectiveness is in treating people who have the disease in its early stages.

Walking into the latter half of 2023, we're looking at a very different stock market than a year ago. Despite elevated interest rates and ongoing inflation, the S&P 500 is up for the fifth consecutive

Quest Diagnostics Inc. DGX, +0.10% said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer's disease to market and it's now available for consumer pu

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.23 per share. This compares to earnings of $2.36 per share a year ago.

Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pand

The "Halftime Report" traders give their top picks to watch for the second half.

Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.

Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.